Skip to Main Content

A coalition of institutional investors is pushing Eli Lilly (LLY) to adopt a policy to disclose when executive pay is clawed back for misconduct. But the company is refusing to do so, even though more than a dozen large drug makers, wholesalers, and retailers have agreed to take such a step.

The rationale for the move, which was made in a shareholder proposal, is that Lilly faces substantial financial, legal, and reputational risks stemming from allegations that the company engaged in anti-competitive pricing over insulin. Specifically, the drug maker faces several lawsuits filed by various U.S. states as well as congressional investigations into allegations of price gouging.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!